Utah Medical Products INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
Brandes Investment Partners, L.P. and Datum One Series Trust have disclosed a combined beneficial ownership of 14.9% in Utah Medical Products, Inc., signaling a substantial investment position.
NASDAQ
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a 14.12% beneficial ownership stake in Utah Medical Products, Inc.
NASDAQ
The Vanguard Group reports 0% beneficial ownership in Utah Medical Products Inc. common stock following an internal realignment.
NASDAQ
Brandes Investment Partners, L.P. has reported a 10.4% beneficial ownership stake in Utah Medical Products Inc., holding 333,204 common shares.
NASDAQ
Brandes Investment Partners, L.P. has disclosed a 7.39% beneficial ownership stake in Utah Medical Products Inc. common shares.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.3% of Utah Medical Products Inc.'s common stock as of June 30, 2025.
NASDAQ
Dimensional Fund Advisors LP has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Utah Medical Products Inc. common stock as of June 30, 2025.
NASDAQ
Brandes Investment Partners, L.P. has filed a Schedule 13G, reporting beneficial ownership of 242,421 common shares, representing 7.4% of Utah Medical Products Inc.
NASDAQ
BlackRock, Inc. has filed an updated Schedule 13G, reporting a 4.97% beneficial ownership stake in Utah Medical Products Inc. as of December 31, 2024, held for ordinary course of business purposes.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.7% in Utah Medical Products Inc. as of December 31, 2024.